{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:38:48Z","timestamp":1794206328874,"version":"4.8.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"],"award-info":[{"award-number":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"],"award-info":[{"award-number":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG067501"],"award-info":[{"award-number":["R01AG067501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG067501"],"award-info":[{"award-number":["R01AG067501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG067501"],"award-info":[{"award-number":["R01AG067501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG067501"],"award-info":[{"award-number":["R01AG067501"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"],"award-info":[{"award-number":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"],"award-info":[{"award-number":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"],"award-info":[{"award-number":["R56AG063908, R01AG067501, RF1AG015473, R01AG072474, R01AG066107"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001873"],"award-info":[{"award-number":["5UL1TR001873"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001873"],"award-info":[{"award-number":["5UL1TR001873"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001873"],"award-info":[{"award-number":["5UL1TR001873"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001873"],"award-info":[{"award-number":["5UL1TR001873"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001873"],"award-info":[{"award-number":["5UL1TR001873"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"DOI":"10.1038\/s43587-025-01025-7","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T10:03:28Z","timestamp":1765965808000},"page":"221-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lysophosphatidylcholines are associated with amyloidosis in early stages of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Vrinda","family":"Kalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Reyes-Dumeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3587-9723","authenticated-orcid":false,"given":"Hanisha","family":"Udhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Lantigua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diones","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9703-2265","authenticated-orcid":false,"given":"Lawrence S.","family":"Honig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-9696","authenticated-orcid":false,"given":"Richard","family":"Mayeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8984-1284","authenticated-orcid":false,"given":"Gary W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-4085","authenticated-orcid":false,"given":"Badri N.","family":"Vardarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/brain\/awz384","volume":"143","author":"A Badhwar","year":"2020","unstructured":"Badhwar, A. et al. A multiomics approach to heterogeneity in Alzheimer\u2019s disease: focused review and roadmap. Brain 143, 1315\u20131331 (2020).","journal-title":"Brain"},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrm.2016.25","volume":"17","author":"CH Johnson","year":"2016","unstructured":"Johnson, C. H., Ivanisevic, J. & Siuzdak, G. Metabolomics: beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol. 17, 451\u2013459 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1025_CR3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/alz.12468","volume":"18","author":"E Horgusluoglu","year":"2022","unstructured":"Horgusluoglu, E. et al. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer\u2019s disease. Alzheimers Dement. 18, 1260\u20131278 (2022).","journal-title":"Alzheimers Dement."},{"key":"1025_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3389\/fneur.2017.00719","volume":"8","author":"JM Wilkins","year":"2017","unstructured":"Wilkins, J. M. & Trushina, E. Application of metabolomics in Alzheimer\u2019s disease. Front. Neurol. 8, 719 (2017).","journal-title":"Front. Neurol."},{"key":"1025_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neurobiolaging.2019.10.014","volume":"86","author":"Z Huo","year":"2020","unstructured":"Huo, Z. et al. Brain and blood metabolome for Alzheimer\u2019s dementia: findings from a targeted metabolomics analysis. Neurobiol. Aging 86, 123\u2013133 (2020).","journal-title":"Neurobiol. Aging"},{"key":"1025_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2478\/jtim-2022-0024","volume":"10","author":"L Yu","year":"2022","unstructured":"Yu, L., Jin, J., Xu, Y. & Zhu, X. Aberrant energy metabolism in Alzheimer\u2019s disease. J. Transl. Int. Med. 10, 197\u2013206 (2022).","journal-title":"J. Transl. Int. Med."},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-020-03160-0","volume":"590","author":"PS Minhas","year":"2021","unstructured":"Minhas, P. S. et al. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature 590, 122\u2013128 (2021).","journal-title":"Nature"},{"key":"1025_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5534\/wjmh.200112","volume":"39","author":"A Bartke","year":"2021","unstructured":"Bartke, A., Brannan, S., Hascup, E., Hascup, K. & Darcy, J. Energy metabolism and aging. World J. Mens. Health 39, 222\u2013232 (2021).","journal-title":"World J. Mens. Health"},{"key":"1025_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-020-0072-x","volume":"19","author":"SC Cunnane","year":"2020","unstructured":"Cunnane, S. C. et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat. Rev. Drug Discov. 19, 609\u2013633 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1025_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02251132","volume":"3","author":"S Hoyer","year":"1991","unstructured":"Hoyer, S., Nitsch, R. & Oesterreich, K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J. Neural Transm. Park Dis. Dement. Sect. 3, 1\u201314 (1991).","journal-title":"J. Neural Transm. Park Dis. Dement. Sect."},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jalz.2017.09.011","volume":"14","author":"Y An","year":"2018","unstructured":"An, Y. et al. Evidence for brain glucose dysregulation in Alzheimer\u2019s disease. Alzheimers Dement. 14, 318\u2013329 (2018).","journal-title":"Alzheimers Dement."},{"key":"1025_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.52","volume":"5","author":"C Madeira","year":"2015","unstructured":"Madeira, C. et al. D-serine levels in Alzheimer\u2019s disease: implications for novel biomarker development. Transl. Psychiatry 5, e561 (2015).","journal-title":"Transl. Psychiatry"},{"key":"1025_CR13","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1523\/JNEUROSCI.2262-17.2018","volume":"38","author":"L Wu","year":"2018","unstructured":"Wu, L., Zhang, X. & Zhao, L. Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer\u2019s disease risk reduction and early intervention. J. Neurosci. 38, 6665\u20136681 (2018).","journal-title":"J. Neurosci."},{"key":"1025_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.pnpbp.2003.11.009","volume":"28","author":"K Hashimoto","year":"2004","unstructured":"Hashimoto, K. et al. Possible role of D-serine in the pathophysiology of Alzheimer\u2019s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 28, 385\u2013388 (2004).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang, W., Zhao, F., Ma, X., Perry, G. & Zhu, X. Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances. Mol. Neurodegener. 15, 30 (2020).","journal-title":"Mol. Neurodegener."},{"key":"1025_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2174\/1570159X18666200525020259","volume":"18","author":"RA Quntanilla","year":"2020","unstructured":"Quntanilla, R. A. & Tapia-Monsalves, C. The role of mitochondrial impairment in Alzheimer s disease neurodegeneration: the tau connection. Curr. Neuropharmacol. 18, 1076\u20131091 (2020).","journal-title":"Curr. Neuropharmacol."},{"key":"1025_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11813-6","volume":"10","author":"P Jadiya","year":"2019","unstructured":"Jadiya, P. et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer\u2019s disease. Nat. Commun. 10, 3885 (2019).","journal-title":"Nat. Commun."},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"662242","DOI":"10.3389\/fnins.2021.662242","volume":"15","author":"X Zhang","year":"2021","unstructured":"Zhang, X., Alshakhshir, N. & Zhao, L. Glycolytic metabolism, brain resilience, and Alzheimer\u2019s disease. Front. Neurosci. 15, 662242 (2021).","journal-title":"Front. Neurosci."},{"key":"1025_CR19","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/ijms14011310","volume":"14","author":"M Kosicek","year":"2013","unstructured":"Kosicek, M. & Hecimovic, S. Phospholipids and Alzheimer\u2019s disease: alterations, mechanisms and potential biomarkers. Int J. Mol. Sci. 14, 1310\u20131322 (2013).","journal-title":"Int J. Mol. Sci."},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neurobiolaging.2013.08.001","volume":"35","author":"L Whiley","year":"2014","unstructured":"Whiley, L. et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer\u2019s disease. Neurobiol. Aging 35, 271\u2013278 (2014).","journal-title":"Neurobiol. Aging"},{"key":"1025_CR21","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/febs.16344","volume":"290","author":"F Yin","year":"2023","unstructured":"Yin, F. Lipid metabolism and Alzheimer\u2019s disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J. 290, 1420\u20131453 (2023).","journal-title":"FEBS J."},{"key":"1025_CR22","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1096\/fj.201801412R","volume":"33","author":"RP Patrick","year":"2019","unstructured":"Patrick, R. P. Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer\u2019s disease. FASEB J. 33, 1554\u20131564 (2019).","journal-title":"FASEB J."},{"key":"1025_CR23","doi-asserted-by":"publisher","first-page":"5472792","DOI":"10.1155\/2017\/5472792","volume":"2017","author":"JW Griffin","year":"2017","unstructured":"Griffin, J. W. & Bradshaw, P. C. Amino acid catabolism in Alzheimer\u2019s disease brain: friend or foe? Oxid. Med. Cell Longev. 2017, 5472792 (2017).","journal-title":"Oxid. Med. Cell Longev."},{"key":"1025_CR24","doi-asserted-by":"publisher","unstructured":"Savonije, K. & Weaver, D. F. The role of tryptophan metabolism in Alzheimer\u2019s disease. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci13020292 (2023).","DOI":"10.3390\/brainsci13020292"},{"key":"1025_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3233\/JAD-210461","volume":"83","author":"P Liu","year":"2021","unstructured":"Liu, P. et al. Phenylalanine metabolism is dysregulated in human hippocampus with Alzheimer\u2019s disease related pathological changes. J. Alzheimers Dis. 83, 609\u2013622 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"1025_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-020-00741-z","volume":"13","author":"L Whiley","year":"2021","unstructured":"Whiley, L. et al. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer\u2019s disease. Alzheimers Res. Ther. 13, 20 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"1025_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2021.147481","volume":"1765","author":"A McCann","year":"2021","unstructured":"McCann, A. et al. Serum tyrosine is associated with better cognition in Lewy body dementia. Brain Res. 1765, 147481 (2021).","journal-title":"Brain Res."},{"key":"1025_CR28","first-page":"e12064","volume":"12","author":"I Hajjar","year":"2020","unstructured":"Hajjar, I., Liu, C., Jones, D. P. & Uppal, K. Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD. Alzheimers Dement. 12, e12064 (2020).","journal-title":"Alzheimers Dement."},{"key":"1025_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02252924","volume":"2","author":"H Basun","year":"1990","unstructured":"Basun, H. et al. Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer\u2019s disease and healthy control subjects. J. Neural Transm. Park Dis. Dement. Sect. 2, 295\u2013304 (1990).","journal-title":"J. Neural Transm. Park Dis. Dement. Sect."},{"key":"1025_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00726-006-0409-8","volume":"32","author":"AN Fonteh","year":"2007","unstructured":"Fonteh, A. N., Harrington, R. J., Tsai, A., Liao, P. & Harrington, M. G. Free amino acid and dipeptide changes in the body fluids from Alzheimer\u2019s disease subjects. Amino Acids 32, 213\u2013224 (2007).","journal-title":"Amino Acids"},{"key":"1025_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jpba.2014.10.010","volume":"107","author":"R Gonzalez-Dominguez","year":"2015","unstructured":"Gonzalez-Dominguez, R., Garcia-Barrera, T. & Gomez-Ariza, J. L. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer\u2019s disease. J. Pharm. Biomed. Anal. 107, 75\u201381 (2015).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"1025_CR32","doi-asserted-by":"publisher","first-page":"8532","DOI":"10.1021\/ac301243k","volume":"84","author":"C Ibanez","year":"2012","unstructured":"Ibanez, C. et al. Toward a predictive model of Alzheimer\u2019s disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal. Chem. 84, 8532\u20138540 (2012).","journal-title":"Anal. Chem."},{"key":"1025_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12931-1","volume":"7","author":"SC Larsson","year":"2017","unstructured":"Larsson, S. C. & Markus, H. S. Branched-chain amino acids and Alzheimer\u2019s disease: a Mendelian randomization analysis. Sci. Rep. 7, 13604 (2017).","journal-title":"Sci. Rep."},{"key":"1025_CR34","doi-asserted-by":"publisher","unstructured":"Li, H. et al. Defect of branched-chain amino acid metabolism promotes the development of Alzheimer\u2019s disease by targeting the mTOR signaling. Biosci. Rep. https:\/\/doi.org\/10.1042\/bsr20180127 (2018).","DOI":"10.1042\/bsr20180127"},{"key":"1025_CR35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jalz.2016.01.008","volume":"12","author":"HH Ruiz","year":"2016","unstructured":"Ruiz, H. H. et al. Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer\u2019s disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. Alzheimers Dement. 12, 851\u2013861 (2016).","journal-title":"Alzheimers Dement"},{"key":"1025_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","volume":"13","author":"JB Toledo","year":"2017","unstructured":"Toledo, J. B. et al. Metabolic network failures in Alzheimer\u2019s disease: a biochemical road map. Alzheimers Dement. 13, 965\u2013984 (2017).","journal-title":"Alzheimers Dement"},{"key":"1025_CR37","doi-asserted-by":"publisher","first-page":"e63644","DOI":"10.1371\/journal.pone.0063644","volume":"8","author":"E Trushina","year":"2013","unstructured":"Trushina, E., Dutta, T., Persson, X. M., Mielke, M. M. & Petersen, R. C. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer\u2019s disease using metabolomics. PLoS ONE 8, e63644 (2013).","journal-title":"PLoS ONE"},{"key":"1025_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jalz.2018.01.003","volume":"14","author":"J Tynkkynen","year":"2018","unstructured":"Tynkkynen, J. et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer\u2019s disease: a prospective study in eight cohorts. Alzheimers Dement. 14, 723\u2013733 (2018).","journal-title":"Alzheimers Dement."},{"key":"1025_CR39","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3233\/JAD-161118","volume":"57","author":"R Kandimalla","year":"2017","unstructured":"Kandimalla, R. & Reddy, P. H. Therapeutics of neurotransmitters in Alzheimer\u2019s disease. J. Alzheimers Dis. 57, 1049\u20131069 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"1025_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1017\/S1092852900014164","volume":"10","author":"PT Francis","year":"2005","unstructured":"Francis, P. T. The interplay of neurotransmitters in Alzheimer\u2019s disease. CNS Spectr. 10, 6\u20139 (2005).","journal-title":"CNS Spectr."},{"key":"1025_CR41","doi-asserted-by":"publisher","unstructured":"Yang, Z., Zou, Y. & Wang, L. Neurotransmitters in prevention and treatment of Alzheimer\u2019s disease. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24043841 (2023).","DOI":"10.3390\/ijms24043841"},{"key":"1025_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnagi.2016.00031","volume":"8","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Implications of GABAergic neurotransmission in Alzheimer\u2019s disease. Front. Aging Neurosci. 8, 31 (2016).","journal-title":"Front. Aging Neurosci."},{"key":"1025_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","volume":"97","author":"Y Xu","year":"2012","unstructured":"Xu, Y. et al. Neurotransmitter receptors and cognitive dysfunction in Alzheimer\u2019s disease and Parkinson\u2019s disease. Prog. Neurobiol. 97, 1\u201313 (2012).","journal-title":"Prog. Neurobiol."},{"key":"1025_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JAD-190198","volume":"71","author":"I Martinez de Toda","year":"2019","unstructured":"Martinez de Toda, I., Miguelez, L., Vida, C., Carro, E. & De la Fuente, M. Altered redox state in whole blood cells from patients with mild cognitive impairment and Alzheimer\u2019s disease. J. Alzheimers Dis. 71, 153\u2013163 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"1025_CR45","doi-asserted-by":"publisher","first-page":"1003721","DOI":"10.3389\/fnagi.2022.1003721","volume":"14","author":"MI Holubiec","year":"2022","unstructured":"Holubiec, M. I., Gellert, M. & Hanschmann, E. M. Redox signaling and metabolism in Alzheimer\u2019s disease. Front. Aging Neurosci. 14, 1003721 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"1025_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3892\/br.2016.630","volume":"4","author":"WJ Huang","year":"2016","unstructured":"Huang, W. J., Zhang, X. & Chen, W. W. Role of oxidative stress in Alzheimer\u2019s disease. Biomed. Rep. 4, 519\u2013522 (2016).","journal-title":"Biomed. Rep."},{"key":"1025_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield, D. A. & Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 20, 148\u2013160 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"1025_CR48","doi-asserted-by":"publisher","first-page":"e238214","DOI":"10.1001\/jamanetworkopen.2023.8214","volume":"6","author":"LS Honig","year":"2023","unstructured":"Honig, L. S. et al. Evaluation of plasma biomarkers for A\/T\/N classification of Alzheimer disease among adults of Caribbean Hispanic ethnicity. JAMA Netw. Open 6, e238214 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1025_CR49","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia, J. et al. Biomarker changes during 20 years preceding Alzheimer\u2019s disease. N. Engl. J. Med 390, 712\u2013722 (2024).","journal-title":"N. Engl. J. Med"},{"key":"1025_CR50","first-page":"1","volume":"72","author":"T Niwa","year":"2010","unstructured":"Niwa, T. Uremic toxicity of indoxyl sulfate. Nagoya J. Med. Sci. 72, 1\u201311 (2010).","journal-title":"Nagoya J. Med. Sci."},{"key":"1025_CR51","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/advances\/nmaa024","volume":"11","author":"RD Semba","year":"2020","unstructured":"Semba, R. D. Perspective: the potential role of circulating lysophosphatidylcholine in neuroprotection against Alzheimer disease. Adv. Nutr. 11, 760\u2013772 (2020).","journal-title":"Adv. Nutr."},{"key":"1025_CR52","doi-asserted-by":"publisher","unstructured":"Law, S. H. et al. An updated review of lysophosphatidylcholine metabolism in human diseases. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms20051149 (2019).","DOI":"10.3390\/ijms20051149"},{"key":"1025_CR53","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1194\/jlr.P023309","volume":"53","author":"D Schmerler","year":"2012","unstructured":"Schmerler, D. et al. Targeted metabolomics for discrimination of systemic inflammatory disorders in critically ill patients. J. Lipid Res. 53, 1369\u20131375 (2012).","journal-title":"J. Lipid Res."},{"key":"1025_CR54","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00702-003-0007-9","volume":"110","author":"C Mulder","year":"2003","unstructured":"Mulder, C. et al. Decreased lysophosphatidylcholine\/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer\u2019s disease. J. Neural Transm. 110, 949\u2013955 (2003).","journal-title":"J. Neural Transm."},{"key":"1025_CR55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3109\/0284186X.2011.648338","volume":"51","author":"L Fan","year":"2012","unstructured":"Fan, L. et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC\/QTOF\/MS platform. Acta Oncol. 51, 473\u2013479 (2012).","journal-title":"Acta Oncol."},{"key":"1025_CR56","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1074\/jbc.M111.274142","volume":"287","author":"RB Chan","year":"2012","unstructured":"Chan, R. B. et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287, 2678\u20132688 (2012).","journal-title":"J. Biol. Chem."},{"key":"1025_CR57","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1016\/j.chroma.2011.07.073","volume":"1218","author":"MO Grimm","year":"2011","unstructured":"Grimm, M. O. et al. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer\u2019s disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A 1218, 7713\u20137722 (2011).","journal-title":"J. Chromatogr. A"},{"key":"1025_CR58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JAD-170554","volume":"61","author":"JG Villamil-Ortiz","year":"2018","unstructured":"Villamil-Ortiz, J. G. et al. Differential pattern of phospholipid profile in the temporal cortex from E280A-familiar and sporadic Alzheimer's disease brains. J. Alzheimers Dis. 61, 209\u2013219 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"1025_CR59","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1046\/j.1471-4159.1998.70020786.x","volume":"70","author":"BM Ross","year":"1998","unstructured":"Ross, B. M., Moszczynska, A., Erlich, J. & Kish, S. J. Phospholipid-metabolizing enzymes in Alzheimer\u2019s disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J. Neurochem. 70, 786\u2013793 (1998).","journal-title":"J. Neurochem."},{"key":"1025_CR60","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.clinbiochem.2010.04.072","volume":"43","author":"NJ Li","year":"2010","unstructured":"Li, N. J. et al. Plasma metabolic profiling of Alzheimer\u2019s disease by liquid chromatography\/mass spectrometry. Clin. Biochem. 43, 992\u2013997 (2010).","journal-title":"Clin. Biochem."},{"key":"1025_CR61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1871524915666141216161246","volume":"14","author":"Y Liu","year":"2014","unstructured":"Liu, Y., Li, N., Zhou, L., Li, Q. & Li, W. Plasma metabolic profiling of mild cognitive impairment and Alzheimer\u2019s disease using liquid chromatography\/mass spectrometry. Cent. Nerv. Syst. Agents Med. Chem. 14, 113\u2013120 (2014).","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"1025_CR62","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/NEN.0000000000000116","volume":"73","author":"Y Cui","year":"2014","unstructured":"Cui, Y. et al. Lysophosphatidylcholine and amide as metabolites for detecting Alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics. J. Neuropathol. Exp. Neurol. 73, 954\u2013963 (2014).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1025_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jprot.2014.01.014","volume":"104","author":"R Gonzalez-Dominguez","year":"2014","unstructured":"Gonzalez-Dominguez, R., Garcia-Barrera, T. & Gomez-Ariza, J. L. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer\u2019s disease. J. Proteom. 104, 37\u201347 (2014).","journal-title":"J. Proteom."},{"key":"1025_CR64","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jalz.2015.12.008","volume":"12","author":"R Casanova","year":"2016","unstructured":"Casanova, R. et al. Blood metabolite markers of preclinical Alzheimer\u2019s disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 12, 815\u2013822 (2016).","journal-title":"Alzheimers Dement."},{"key":"1025_CR65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/neup.12182","volume":"35","author":"Y Inose","year":"2015","unstructured":"Inose, Y., Kato, Y., Kitagawa, K., Uchiyama, S. & Shibata, N. Activated microglia in ischemic stroke penumbra upregulate MCP-1 and CCR2 expression in response to lysophosphatidylcholine derived from adjacent neurons and astrocytes. Neuropathology 35, 209\u2013223 (2015).","journal-title":"Neuropathology"},{"key":"1025_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neuroscience.2015.02.034","volume":"292","author":"AM Sheikh","year":"2015","unstructured":"Sheikh, A. M., Michikawa, M., Kim, S. U. & Nagai, A. Lysophosphatidylcholine increases the neurotoxicity of Alzheimer\u2019s amyloid \u03b21-42 peptide: role of oligomer formation. Neuroscience 292, 159\u2013169 (2015).","journal-title":"Neuroscience"},{"key":"1025_CR67","doi-asserted-by":"publisher","unstructured":"Knuplez, E. & Marsche, G. An updated review of pro- and anti-inflammatory properties of plasma lysophosphatidylcholines in the vascular system. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21124501 (2020).","DOI":"10.3390\/ijms21124501"},{"key":"1025_CR68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0006-3223(94)00123-K","volume":"37","author":"WF Gattaz","year":"1995","unstructured":"Gattaz, W. F., Maras, A., Cairns, N. J., Levy, R. & Forstl, H. Decreased phospholipase A2 activity in Alzheimer brains. Biol. Psychiatry 37, 13\u201317 (1995).","journal-title":"Biol. Psychiatry"},{"key":"1025_CR69","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/nn.2213","volume":"11","author":"RO Sanchez-Mejia","year":"2008","unstructured":"Sanchez-Mejia, R. O. et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer\u2019s disease. Nat. Neurosci. 11, 1311\u20131318 (2008).","journal-title":"Nat. Neurosci."},{"key":"1025_CR70","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.bbalip.2010.05.013","volume":"1801","author":"RO Sanchez-Mejia","year":"2010","unstructured":"Sanchez-Mejia, R. O. & Mucke, L. Phospholipase A2 and arachidonic acid in Alzheimer\u2019s disease. Biochim. Biophys. Acta 1801, 784\u2013790 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"1025_CR71","volume":"6","author":"B Vardarajan","year":"2020","unstructured":"Vardarajan, B. et al. Differences in plasma metabolites related to Alzheimer\u2019s disease, APOE epsilon4 status, and ethnicity. Alzheimers Dement. 6, e12025 (2020).","journal-title":"Alzheimers Dement."},{"key":"1025_CR72","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab085","volume":"3","author":"G Coughlan","year":"2021","unstructured":"Coughlan, G. et al. APOE epsilon4 alters associations between docosahexaenoic acid and preclinical markers of Alzheimer\u2019s disease. Brain Commun. 3, fcab085 (2021).","journal-title":"Brain Commun."},{"key":"1025_CR73","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.neurobiolaging.2013.03.012","volume":"34","author":"WL Lim","year":"2013","unstructured":"Lim, W. L. et al. Effects of a high-fat, high-cholesterol diet on brain lipid profiles in apolipoprotein E epsilon3 and epsilon4 knock-in mice. Neurobiol. Aging 34, 2217\u20132224 (2013).","journal-title":"Neurobiol. Aging"},{"key":"1025_CR74","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3233\/JAD-2011-111265","volume":"28","author":"Z Kariv-Inbal","year":"2012","unstructured":"Kariv-Inbal, Z. et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J. Alzheimers Dis. 28, 667\u2013683 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"1025_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01881-6","volume":"12","author":"AM Miranda","year":"2022","unstructured":"Miranda, A. M. et al. Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice. Transl. Psychiatry 12, 129 (2022).","journal-title":"Transl. Psychiatry"},{"key":"1025_CR76","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00726-013-1583-0","volume":"45","author":"O van de Rest","year":"2013","unstructured":"van de Rest, O., van der Zwaluw, N. L. & de Groot, L. C. Literature review on the role of dietary protein and amino acids in cognitive functioning and cognitive decline. Amino Acids 45, 1035\u20131045 (2013).","journal-title":"Amino Acids"},{"key":"1025_CR77","doi-asserted-by":"publisher","first-page":"101800","DOI":"10.1016\/j.pneurobio.2020.101800","volume":"190","author":"M Maitre","year":"2020","unstructured":"Maitre, M., Klein, C., Patte-Mensah, C. & Mensah-Nyagan, A. G. Tryptophan metabolites modify brain A\u03b2 peptide degradation: a role in Alzheimer's disease? Prog. Neurobiol. 190, 101800 (2020).","journal-title":"Prog. Neurobiol."},{"key":"1025_CR78","doi-asserted-by":"publisher","unstructured":"Pathak, S. et al. The influence of kynurenine metabolites on neurodegenerative pathologies. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25020853 (2024).","DOI":"10.3390\/ijms25020853"},{"key":"1025_CR79","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00005072-196504000-00004","volume":"24","author":"K Suzuki","year":"1965","unstructured":"Suzuki, K., Katzman, R. & Korey, S. R. Chemical studies on Alzheimer\u2019s disease. J. Neuropathol. Exp. Neurol. 24, 211\u2013224 (1965).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1025_CR80","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0197-4580(89)90108-5","volume":"10","author":"AD Snow","year":"1989","unstructured":"Snow, A. D. & Wight, T. N. Proteoglycans in the pathogenesis of Alzheimer\u2019s disease and other amyloidoses. Neurobiol. Aging 10, 481\u2013497 (1989).","journal-title":"Neurobiol. Aging"},{"key":"1025_CR81","doi-asserted-by":"publisher","first-page":"710683","DOI":"10.3389\/fnagi.2021.710683","volume":"13","author":"AD Snow","year":"2021","unstructured":"Snow, A. D., Cummings, J. A. & Lake, T. The unifying hypothesis of Alzheimer\u2019s disease: heparan sulfate proteoglycans\/glycosaminoglycans are key as first hypothesized over 30 years ago. Front. Aging Neurosci. 13, 710683 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"1025_CR82","doi-asserted-by":"publisher","first-page":"33118","DOI":"10.1074\/jbc.272.52.33118","volume":"272","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa, M., Crowther, R. A., Jakes, R. & Goedert, M. Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J. Biol. Chem. 272, 33118\u201333124 (1997).","journal-title":"J. Biol. Chem."},{"key":"1025_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24904-z","volume":"8","author":"JN Rauch","year":"2018","unstructured":"Rauch, J. N. et al. Tau internalization is regulated by 6-O sulfation on heparan sulfate proteoglycans (HSPGs). Sci. Rep. 8, 6382 (2018).","journal-title":"Sci. Rep."},{"key":"1025_CR84","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.expneurol.2015.08.004","volume":"274","author":"PD Smith","year":"2015","unstructured":"Smith, P. D., Coulson-Thomas, V. J., Foscarin, S., Kwok, J. C. & Fawcett, J. W. \u2018GAG-ing with the neuron\u2019: the role of glycosaminoglycan patterning in the central nervous system. Exp. Neurol. 274, 100\u2013114 (2015).","journal-title":"Exp. Neurol."},{"key":"1025_CR85","doi-asserted-by":"publisher","first-page":"122629","DOI":"10.1016\/j.biomaterials.2024.122629","volume":"309","author":"AD Evans","year":"2024","unstructured":"Evans, A. D., Pournoori, N., Saksala, E. & Oommen, O. P. Glycosaminoglycans' for brain health: harnessing glycosaminoglycan based biomaterials for treating central nervous system diseases and in-vitro modeling. Biomaterials 309, 122629 (2024).","journal-title":"Biomaterials"},{"key":"1025_CR86","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.matbio.2018.04.010","volume":"71-72","author":"EL Stephenson","year":"2018","unstructured":"Stephenson, E. L. & Yong, V. W. Pro-inflammatory roles of chondroitin sulfate proteoglycans in disorders of the central nervous system. Matrix Biol. 71-72, 432\u2013442 (2018).","journal-title":"Matrix Biol."},{"key":"1025_CR87","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41420-023-01617-5","volume":"9","author":"J Zhao","year":"2023","unstructured":"Zhao, J. & Lang, M. New insight into protein glycosylation in the development of Alzheimer\u2019s disease. Cell Death Discov. 9, 314 (2023).","journal-title":"Cell Death Discov."},{"key":"1025_CR88","doi-asserted-by":"publisher","first-page":"625348","DOI":"10.3389\/fnins.2020.625348","volume":"14","author":"H Haukedal","year":"2020","unstructured":"Haukedal, H. & Freude, K. K. Implications of glycosylation in Alzheimer\u2019s disease. Front. Neurosci. 14, 625348 (2020).","journal-title":"Front. Neurosci."},{"key":"1025_CR89","doi-asserted-by":"publisher","first-page":"648617","DOI":"10.3389\/fnins.2021.648617","volume":"15","author":"P Rawal","year":"2021","unstructured":"Rawal, P. & Zhao, L. Sialometabolism in brain health and Alzheimer\u2019s disease. Front. Neurosci. 15, 648617 (2021).","journal-title":"Front. Neurosci."},{"key":"1025_CR90","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brainres.2007.05.055","volume":"1161","author":"DA Patel","year":"2007","unstructured":"Patel, D. A., Henry, J. E. & Good, T. A. Attenuation of \u03b2-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment. Brain Res. 1161, 95\u2013105 (2007).","journal-title":"Brain Res"},{"key":"1025_CR91","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"1025_CR92","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1097\/JOM.0000000000000773","volume":"58","author":"KH Liu","year":"2016","unstructured":"Liu, K. H. et al. High-resolution metabolomics assessment of military personnel: evaluating analytical strategies for chemical detection. J. Occup. Environ. Med. 58, S53\u2013S61 (2016).","journal-title":"J. Occup. Environ. Med."},{"key":"1025_CR93","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.taap.2018.12.001","volume":"363","author":"DI Walker","year":"2019","unstructured":"Walker, D. I. et al. Metabolome-wide association study of anti-epileptic drug treatment during pregnancy. Toxicol. Appl. Pharm. 363, 122\u2013130 (2019).","journal-title":"Toxicol. Appl. Pharm."},{"key":"1025_CR94","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/bioinformatics\/btp291","volume":"25","author":"T Yu","year":"2009","unstructured":"Yu, T., Park, Y., Johnson, J. M. & Jones, D. P. apLCMS\u2013adaptive processing of high-resolution LC\/MS data. Bioinformatics 25, 1930\u20131936 (2009).","journal-title":"Bioinformatics"},{"key":"1025_CR95","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1021\/acs.analchem.6b01214","volume":"89","author":"K Uppal","year":"2017","unstructured":"Uppal, K., Walker, D. I. & Jones, D. P. xMSannotator: an R package for network-based annotation of high-resolution metabolomics data. Anal. Chem. 89, 1063\u20131067 (2017).","journal-title":"Anal. Chem."},{"key":"1025_CR96","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"1025_CR97","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1021\/es5002105","volume":"48","author":"EL Schymanski","year":"2014","unstructured":"Schymanski, E. L. et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ. Sci. Technol. 48, 2097\u20132098 (2014).","journal-title":"Environ. Sci. Technol."},{"key":"1025_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120805","volume":"453","author":"G Giacomucci","year":"2023","unstructured":"Giacomucci, G. et al. Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer\u2019s disease pathology in subjective cognitive decline and mild cognitive impairment. J. Neurol. Sci. 453, 120805 (2023).","journal-title":"J. Neurol. Sci."},{"key":"1025_CR99","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"1025_CR100","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3233\/JAD-215639","volume":"87","author":"ER McGrath","year":"2022","unstructured":"McGrath, E. R. et al. Blood phosphorylated tau 181 as a biomarker for amyloid burden on brain PET in cognitively healthy adults. J. Alzheimers Dis. 87, 1517\u20131526 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"1025_CR101","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997 (2018).","journal-title":"Alzheimers Dement."},{"key":"1025_CR102","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"1025_CR103","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41592-020-01009-y","volume":"17","author":"E Fahy","year":"2020","unstructured":"Fahy, E. & Subramaniam, S. RefMet: a reference nomenclature for metabolomics. Nat. Methods 17, 1173\u20131174 (2020).","journal-title":"Nat. Methods"},{"key":"1025_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).","journal-title":"BMC Bioinform."},{"key":"1025_CR105","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/bioinformatics\/bty528","volume":"34","author":"J Chong","year":"2018","unstructured":"Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. Bioinformatics 34, 4313\u20134314 (2018).","journal-title":"Bioinformatics"},{"key":"1025_CR106","doi-asserted-by":"publisher","first-page":"e1003123","DOI":"10.1371\/journal.pcbi.1003123","volume":"9","author":"S Li","year":"2013","unstructured":"Li, S. et al. Predicting network activity from high throughput metabolomics. PLoS Comput. Biol. 9, e1003123 (2013).","journal-title":"PLoS Comput. Biol."},{"key":"1025_CR107","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/alz.12714","volume":"19","author":"R Batra","year":"2023","unstructured":"Batra, R. et al. The landscape of metabolic brain alterations in Alzheimer\u2019s disease. Alzheimers Dement. 19, 980\u2013998 (2023).","journal-title":"Alzheimers Dement."}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01025-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01025-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01025-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:03:00Z","timestamp":1769000580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-025-01025-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":107,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1038\/s43587-025-01025-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3346076\/v1","asserted-by":"object"}]},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}